In the in vitro study, where researchers compared membranes to assess cytokines, chronic inflammation became a concern for end-stage renal disease patients.
In a second in vitro study, researchers found that the high-cut off dialyzer membrane provided a more efficient removal of molecules that may affect biological functions, including inflammation and cardiovascular.
“While our findings conclude that targeting these molecules is possible, further research will help us understand the clinical impact of removing these molecules from the blood,” Storr said.
Multiple myeloma is a rare form of cancer, affecting about 7 percent of the U.S. population. For 2016, the American Cancer Society estimated about 12,650 deaths due to complications with multiple myeloma.